Pruxelutamide is under clinical development by Kintor Pharmaceutical and currently in Phase II for Metastatic Castration-Resistant Prostate Cancer (mCRPC). According to GlobalData, Phase II drugs for Metastatic Castration-Resistant Prostate Cancer (mCRPC) have a 33% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Pruxelutamide’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Pruxelutamide overview
Proxalutamide (GT-0918) is under development for the treatment of Coronavirus COVID-19 disease, metastatic hormone-sensitive prostate cancer, hormone senstive, castration resistant prostate cancer (CRPC) and AR positive metastatic breast cancer, HER-2 negative breast cancer and triple negative breast cancer. It is administered through oral and formulated in the form of tablet. The drug candidate acts by targeting androgen receptor.
Kintor Pharmaceutical overview
Kintor Pharmaceutical (Kintor) is a clinical stage drug company. It develops small molecules and biological drugs for dermatology and oncology. The company’s pipeline products include Pyrilutamide (KX-826), AR-PROTAC Compound (GT20029), Pruxelutamide (GT0918), Hedgehog/SMO Inhibitor (GT1708F), Detorsertib (GT0486), ALK-1 Antibody (GT90001) and PD-L1/TGF-ß (GT90008). It offers therapeutic drugs for various diseases such as metastatic castration-resistant prostate cancer, hepatocellular carcinoma, gastric carcinoma, urothelial carcinoma, Leukaemia and other disease. The company operates in Hong Kong, China, and the US. Kintor is headquartered in Suzhou, Jiangsu, China.
For a complete picture of Pruxelutamide’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
